(MMS) Maximus - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5779331041

Business Process Services, Eligibility & Enrollment, Customer Contact Centers, Health & Disability Assessments, Technology

MMS EPS (Earnings per Share)

EPS (Earnings per Share) of MMS over the last years for every Quarter: "2020-09": 1.02, "2020-12": 1.03, "2021-03": 1.29, "2021-06": 1.51, "2021-09": 0.83, "2021-12": 0.85, "2022-03": 0.8, "2022-06": 0.51, "2022-09": 1.13, "2022-12": 0.65, "2023-03": 0.52, "2023-06": 0.5, "2023-09": 0.96, "2023-12": 1.04, "2024-03": 1.31, "2024-06": 1.46, "2024-09": 1.46, "2024-12": 1.61, "2025-03": 2.01, "2025-06": 2.16, "2025-09": 0,

MMS Revenue

Revenue of MMS over the last years for every Quarter: 2020-09: 923.836, 2020-12: 945.554, 2021-03: 959.28, 2021-06: 1243.52, 2021-09: 1106.131, 2021-12: 1150.876, 2022-03: 1177.326, 2022-06: 1125.785, 2022-09: 1177.031, 2022-12: 1249.246, 2023-03: 1206.852, 2023-06: 1188.677, 2023-09: 1259.953, 2023-12: 1327.041, 2024-03: 1348.357, 2024-06: 1314.929, 2024-09: 1315.87, 2024-12: 1402.675, 2025-03: 1361.786, 2025-06: 1348.4, 2025-09: null,

Description: MMS Maximus November 07, 2025

Maximus, Inc. (NYSE:MMS) is a global provider of outsourced government services organized into three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The Federal Services arm delivers business-process outsourcing, eligibility and enrollment, clinical and technology solutions-including advanced analytics, cybersecurity, and cloud modernization-for federal health and human-services programs. The U.S. Services segment focuses on multi-channel enrollment support, beneficiary outreach, and a suite of employment-service offerings such as case management and job-readiness programs. The Outside the U.S. segment extends similar business-process and technology solutions to international governments, covering health assessments, employment-service administration, and digital customer-service platforms.

Key recent metrics underline the company’s growth trajectory: FY 2023 revenue reached approximately $5.2 billion, up 8 % year-over-year, driven largely by expanding Medicaid and unemployment-benefits contracts; the operating margin held steady near 9 %, reflecting disciplined cost management amid higher labor costs. The backlog of signed contracts-estimated at $13 billion-provides a multi-year revenue runway, while FY 2024 guidance anticipates double-digit top-line growth, supported by increased federal spending on health-care modernization and state-level workforce-development initiatives. Macro-level, the sector benefits from a sustained policy trend toward outsourcing non-core government functions and from demographic pressures that raise demand for health-service eligibility processing.

For a deeper, data-driven view of Maximus’s valuation dynamics and scenario analysis, you may find the research tools on ValueRay worth exploring.

MMS Stock Overview

Market Cap in USD 4,684m
Sub-Industry Data Processing & Outsourced Services
IPO / Inception 1997-06-12

MMS Stock Ratings

Growth Rating 37.3%
Fundamental 65.5%
Dividend Rating 51.0%
Return 12m vs S&P 500 -16.6%
Analyst Rating 4.0 of 5

MMS Dividends

Dividend Yield 12m 1.78%
Yield on Cost 5y 2.19%
Annual Growth 5y 1.74%
Payout Consistency 96.9%
Payout Ratio 20.8%

MMS Growth Ratios

Growth Correlation 3m -18.2%
Growth Correlation 12m 43.2%
Growth Correlation 5y 19.3%
CAGR 5y 12.12%
CAGR/Max DD 3y (Calmar Ratio) 0.40
CAGR/Mean DD 3y (Pain Ratio) 1.35
Sharpe Ratio 12m -0.24
Alpha -15.30
Beta 0.567
Volatility 24.91%
Current Volume 439.4k
Average Volume 20d 439.4k
Stop Loss 81.5 (-3.1%)
Signal 0.62

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (316.2m TTM) > 0 and > 6% of Revenue (6% = 325.7m TTM)
FCFTA -0.03 (>2.0%) and ΔFCFTA -12.32pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 16.56% (prev 7.59%; Δ 8.97pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.01 (>3.0%) and CFO -56.2m <= Net Income 316.2m (YES >=105%, WARN >=100%)
Net Debt (1.72b) to EBITDA (648.1m) ratio: 2.66 <= 3.0 (WARN <= 3.5)
Current Ratio 2.27 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (57.0m) change vs 12m ago -7.16% (target <= -2.0% for YES)
Gross Margin 23.98% (prev 23.22%; Δ 0.75pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 128.3% (prev 131.3%; Δ -2.96pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 6.35 (EBITDA TTM 648.1m / Interest Expense TTM 81.7m) >= 6 (WARN >= 3)

Altman Z'' 3.68

(A) 0.20 = (Total Current Assets 1.61b - Total Current Liabilities 706.2m) / Total Assets 4.46b
(B) 0.26 = Retained Earnings (Balance) 1.16b / Total Assets 4.46b
(C) 0.12 = EBIT TTM 518.7m / Avg Total Assets 4.23b
(D) 0.66 = Book Value of Equity 1.77b / Total Liabilities 2.69b
Total Rating: 3.68 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 65.51

1. Piotroski 4.50pt = -0.50
2. FCF Yield -2.25% = -1.12
3. FCF Margin -2.65% = -0.99
4. Debt/Equity 1.00 = 2.02
5. Debt/Ebitda 2.66 = -1.23
6. ROIC - WACC (= 6.08)% = 7.60
7. RoE 18.25% = 1.52
8. Rev. Trend 86.98% = 6.52
9. EPS Trend 33.88% = 1.69

What is the price of MMS shares?

As of November 08, 2025, the stock is trading at USD 84.08 with a total of 439,400 shares traded.
Over the past week, the price has changed by +1.15%, over one month by -6.82%, over three months by +7.76% and over the past year by -4.93%.

Is Maximus a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Maximus (NYSE:MMS) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 65.51 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MMS is around 79.55 USD . This means that MMS is currently overvalued and has a potential downside of -5.39%.

Is MMS a buy, sell or hold?

Maximus has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy MMS.
  • Strong Buy: 0
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the MMS price?

Issuer Target Up/Down from current
Wallstreet Target Price 105 24.9%
Analysts Target Price 105 24.9%
ValueRay Target Price 86.8 3.3%

MMS Fundamental Data Overview November 04, 2025

Market Cap USD = 4.68b (4.68b USD * 1.0 USD.USD)
P/E Trailing = 15.4498
P/E Forward = 18.2482
P/S = 0.8628
P/B = 2.9001
P/EG = 2.0716
Beta = 0.567
Revenue TTM = 5.43b USD
EBIT TTM = 518.7m USD
EBITDA TTM = 648.1m USD
Long Term Debt = 1.61b USD (from longTermDebt, last quarter)
Short Term Debt = 88.1m USD (from shortTermDebt, last quarter)
Debt = 1.78b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.72b USD (from netDebt column, last quarter)
Enterprise Value = 6.40b USD (4.68b + Debt 1.78b - CCE 59.8m)
Interest Coverage Ratio = 6.35 (Ebit TTM 518.7m / Interest Expense TTM 81.7m)
FCF Yield = -2.25% (FCF TTM -143.8m / Enterprise Value 6.40b)
FCF Margin = -2.65% (FCF TTM -143.8m / Revenue TTM 5.43b)
Net Margin = 5.83% (Net Income TTM 316.2m / Revenue TTM 5.43b)
Gross Margin = 23.98% ((Revenue TTM 5.43b - Cost of Revenue TTM 4.13b) / Revenue TTM)
Gross Margin QoQ = 26.66% (prev 24.88%)
Tobins Q-Ratio = 1.44 (Enterprise Value 6.40b / Total Assets 4.46b)
Interest Expense / Debt = 1.27% (Interest Expense 22.7m / Debt 1.78b)
Taxrate = 25.87% (37.0m / 143.0m)
NOPAT = 384.5m (EBIT 518.7m * (1 - 25.87%))
Current Ratio = 2.27 (Total Current Assets 1.61b / Total Current Liabilities 706.2m)
Debt / Equity = 1.00 (Debt 1.78b / totalStockholderEquity, last quarter 1.77b)
Debt / EBITDA = 2.66 (Net Debt 1.72b / EBITDA 648.1m)
Debt / FCF = -11.97 (negative FCF - burning cash) (Net Debt 1.72b / FCF TTM -143.8m)
Total Stockholder Equity = 1.73b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.09% (Net Income 316.2m / Total Assets 4.46b)
RoE = 18.25% (Net Income TTM 316.2m / Total Stockholder Equity 1.73b)
RoCE = 15.52% (EBIT 518.7m / Capital Employed (Equity 1.73b + L.T.Debt 1.61b))
RoIC = 12.21% (NOPAT 384.5m / Invested Capital 3.15b)
WACC = 6.13% (E(4.68b)/V(6.46b) * Re(8.10%) + D(1.78b)/V(6.46b) * Rd(1.27%) * (1-Tc(0.26)))
Discount Rate = 8.10% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.77%
Fair Price DCF = unknown (Cash Flow -143.8m)
EPS Correlation: 33.88 | EPS CAGR: -49.46% | SUE: -4.0 | # QB: 0
Revenue Correlation: 86.98 | Revenue CAGR: 5.07% | SUE: 0.75 | # QB: 0

Additional Sources for MMS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle